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The first Banff proposal for the diagnosis of pancreas
rejection (Am J Transplant 2008; 8: 237) dealt primar-
ily with the diagnosis of acute T-cell-mediated rejec-
tion (ACMR), while only tentatively addressing issues
pertaining to antibody-mediated rejection (AMR). This
document presents comprehensive guidelines for the
diagnosis of AMR, first proposed at the 10th Banff Con-
ference on Allograft Pathology and refined by a broad-
based multidisciplinary panel. Pancreatic AMR is best
identified by a combination of serological and im-
munohistopathological findings consisting of (i) iden-
tification of circulating donor-specific antibodies, and
histopathological data including (ii) morphological ev-
idence of microvascular tissue injury and (iii) C4d
staining in interacinar capillaries. Acute AMR is diag-
nosed conclusively if these three elements are present,
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whereas a diagnosis of suspicious for AMR is rendered
if only two elements are identified. The identification of
only one diagnostic element is not sufficient for the di-
agnosis of AMR but should prompt heightened clinical
vigilance. AMR and ACMR may coexist, and should be
recognized and graded independently. This proposal is
based on our current knowledge of the pathogenesis of
pancreas rejection and currently available tools for di-
agnosis. A systematized clinicopathological approach
to AMR is essential for the development and assess-
ment of much needed therapeutic interventions.
Key words: Acinar cell injury, active chronic antibody-
mediated rejection, amylin, amyloid, C4d, cell-
mediated rejection, donor-specific antibody, in-
teracinar capillaries, pancreas biopsy, transplant
arteriopathy
Abbreviations: AMR, antibody-mediated rejection;
ACMR, acute T-cell-mediated allograft rejection; DSA,
donor-specific antibody; MHC, major histocompatibil-
ity complex; MICA, MHC class I–related chain A; IAC,
interacinar capillaries in pancreatic exocrine lobules;
IAPP, islet amyloid polypeptide; IVIG, intravenous im-
mune globulin; PRA, panel-reactive antibody; SMA,
smooth-muscle antibody.
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Introduction
Over the past three decades, refinements in surgical tech-
niques and greater understanding of the histopathological
features of allograft rejection have been achieved in vas-
cularized pancreas transplantation (1–9). Moreover, major
pharmacological advances have been made in the preven-
tion and treatment of classical acute T-cell-mediated allo-
graft rejection (ACMR) leading to higher expectations for
improved short- and long-term outcomes. Unfortunately,
in spite of a reduction in the rates of early acute rejection,
long-term outcomes have not improved markedly, because
some subsets of patients continued to lose their grafts to
intractable rejection or to slow but inexorable progression
to graft fibrosis (10,11).
In recent years an increasing number of cases of pan-
creas allograft dysfunction and loss attributed to antibody-
mediated allograft rejection (AMR) have been reported in
the literature (6,11–15). AMR which does not respond to
standard treatments for ACMR is caused by antibodies
directed against donor-specific human leukocyte antigen
(HLA) molecules or other cellular antigens (12,16,17). AMR
can result from a strong anamnestic antibody response
to previous antigenic exposure (i.e. retransplantation and
pregnancy) or from de novo development of donor-specific
antibody (DSA; Ref. 11). The development of AMR was
documented in a pancreas-transplant recipient who was
presensitized after two previous islet transplantations (18)
and has also been reported in association with viral infec-
tions (19,20).
AMR causes graft failure through acute and/or chronic im-
munoglobulin and complement induced microvascular in-
jury and remodeling that eventually leads to graft fibrosis
(21,22). It has been postulated that chronic AMR is the sin-
gle most important factor limiting long-term graft survival
in solid organ transplantation (21,23,24). The interplay be-
tween AMR and autoimmunity is currently unknown (25),
but anti-HLA DSA and AMR have also been reported in as-
sociation with recurrence of autoimmune diabetes mellitus
(14).
Distribution of HLA Class I and Class II in pancreas
tissue
Major histocompatibility complex (MHC) disparities have
been associated with an increased risk of humoral rejection
and graft loss (26), but in practice minimal emphasis is
placed on HLA matching in simultaneous kidney-pancreas
transplantation. HLA matching may have a greater role in
solitary pancreas transplantation, in which the incidences
of ACMR and immunological graft loss are inherently higher
(1).
The normal pancreas expresses MHC Classes I and II differ-
ently in the exocrine and endocrine components (27–29).
Expression is altered in inflammatory conditions, including
ACMR, which is typically associated with aberrant expres-
sion of Class I and Class II antigens (30–33). Similarly, with
the development of diabetes mellitus there is hyperexpres-
sion of Class I antigens and aberrant expression of Class II
antigens in the endocrine islets (34; Table 1).
Considerations on DSA testing
Prevention, diagnosis and treatment of AMR require mon-
itoring for the presence of circulating DSA (35). It is rec-
ommended that routine antibody monitoring be performed
at regular intervals after transplantation, as well as at the
time of biopsy, and whenever rejection is suspected (36).
Specific clinical settings may warrant development and im-
plementation of protocols tailored to individual patients
(i.e. desensitization protocols, weaning of immunosup-
pression, etc.) (37).
In recent years, marked improvements in the sensitivity
and specificity for detecting alloantibodies have led to on-
going assessment of the clinical relevance of anti-HLA an-
tibody levels, specificities and the significance of antibod-
ies to non-HLA antigens (e.g. MHC class I–related chain
A [MICA], auto antigens) and to non-AB-DR HLA antigens
(37–39). Although an earlier study found a strong associ-
ation between DSA to MHC Class II and chronic allograft
rejection/graft loss (26), subsequent studies have not found
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Table 1: Class I and II HLA expression in normal and abnormal pancreas tissue∗
Normal pancreas
histology sections
Tissue culture–inflammatory milieu (ß
IFN, c IFN and IL2) Diabetes mellitus (DM)
Cell type Class I Class II Class I Class II Class I Class II
Acinar cells − − + + n/a n/a
Aberrant expression Aberrant
expression
Ductal cells ++ − ++ + n/a n/a
Aberrant
expression











Capillary endothelium ++ ++ n/a n/a n/a n/a
Large vessel endothelium ++ Variable n/a n/a n/a n/a
∗Based on Refs. 10–17.
n/a = data not available.
significant clinicopathological differences between DSA to
Class I and Class II antigens (6,12,15). Antibodies to MICA
were associated with histopathological features of AMR in
the pancreas in one series (15)
Although there has been remarkable progress to date,
much work remains to be done in the area of histo-
compatibility and immunogenetics in order to better un-




Circulating DSA directed against endothelial cells leads to
widespread activation of the complement and coagulation
cascades in the vascular walls with consequent mobiliza-
tion of a variety of inflammatory mediators. Demonstra-
tion of immunoglobulins and active complement compo-
nents in the microvasculature has proven difficult due to
the rapid turnover and degradation of the various products
(40). In contrast, the complement fragment C4d which
is generated through the classical (antibody-induced) ac-
tivation pathway is resistant to shedding and degrada-
tion and remains detectable in the vessel walls for at
least several days following the initial immunological event
(17,40,41).
Multiple studies have demonstrated that C4d staining in
renal biopsies performed for allograft dysfunction is predic-
tive of poorer graft outcomes and helps identify patients
with AMR (16). In pancreas allograft biopsies, C4d staining
is typically absent in cases of pure ACMR or in protocol
biopsies from well-functioning grafts (6,12).
More recently, it has been emphasized that C4d staining
alone lacks enough sensitivity and specificity to be used as
an unequivocal marker for the presence or absence of re-
nal AMR, especially late posttransplant (42,43). However,
microvascular inflammation/injury with concurrent detec-
tion of circulating DSA can identify AMR independently of
positive C4d staining (22,44). For practical purposes, it is
generally agreed that the clinical diagnosis of AMR is best
achieved with a combination of careful histological evalua-
tion, including C4d staining and correlation with concurrent
DSA evaluation (9,45).
Technical aspects and interpretation
There is general consensus that C4d staining should be per-
formed in pancreas allograft biopsies in addition to the stan-
dard set of slides and stains (Hematoxylin and Eosin [H&E]
×3 and Masson’s trichrome stain; Ref. 9). Both immuno-
histochemical and immunofluorescence C4d stains are ad-
equate for diagnosis and yield a similar staining pattern in
interacinar capillaries (IAC; Figure 1). In renal and cardiac
allograft biopsies, the immunofluorescence technique has
been reported to yield stronger staining compared to the
immunohistochemical method but the difference was not
considered significant for clinical purposes (45,46). Com-
parison of the two methods in pancreas allograft biopsies,
showed that with the immunofluorescence technique the
estimated areas of lobular IAC staining were 10–50% larger
than with the immunohistochemical method (E. Rangel,
D. U. Kim and P. Revelo, ongoing data collection). Based
on these preliminary data and the earlier work by Torre-
alba et al. (6), it is recommended that the threshold for
C4d positivity in pancreas-allograft biopsies should remain
at ≥5% (9), until additional data become available. When
immunohistochemical staining is used, a low threshold is
preferable, considering that several studies in the kidney
1794 American Journal of Transplantation 2011; 11: 1792–1802
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Figure 1: C4d staining in






Dr. Revelo). (C) Atrophic
lobule in chronic active
AMR shows strong C4d
positivity in residual interaci-
nar capillaries. The acinar
component is atrophic.
Note “lobular” arrangement
of the staining capillaries.
(D) C4d staining in severe
acute AMR. Due to exten-
sive parenchymal necrosis
there is nonspecific back-




shows positive staining in
its wall and contents.
have shown that both focal and diffuse C4d staining were
associated with poorer graft outcomes (17,47). In a patient
with pancreatic AMR, semiquantitive evaluation of inten-
sity and extent of C4d staining in serial biopsies was found
to correlate with DSA levels (S. Seshan, personal observa-
tion).
C4d staining in parenchymal-IAC is to be reported semi-
quantitatively based on the extent of exocrine lobular
biopsy surface staining, as follows: Negative <5%, Fo-
cal 5–50% and Diffuse >50%. Only linear or granular
staining along the IAC correlates with the presence of
circulating DSA (6,12). In contrast, staining in other tis-
sue components such as the endothelium of larger ves-
sels including veins and arteries, the interstitial or sep-
tal connective tissue or the peripancreatic soft tissues is
considered nonspecific (6). In biopsies with chronic active
AMR (see later), the lobular architecture is expected to be
disrupted by interstitial fibrosis and acinar atrophy and it
may be more difficult to identify the IAC. On the other
hand, despite the sclerosing architectural changes, C4d
positivity typically remains in residual capillary vessels of-
ten with partial preservation of the lobular arrangement
(Figure 1C).
In severe AMR with extensive parenchymal necrosis, most
of the IAC staining could be lost. In contrast, strong C4d
staining is typically found in the necrotic vascular walls
(Figure 1D). Correlation with DSA studies is strongly rec-
ommended in this setting.
Clinicopathological Spectrum of AMR in
Pancreas Allografts
Hyperacute rejection
The inescapable effects of preformed antidonor antibodies
leading to “hyperacute rejection” and immediate graft de-
struction were identified early in the history of solid organ
transplantation as a strong immunological barrier to suc-
cessful engraftment. With respect to pancreas transplan-
tation, the recognition of hyperacute rejection has been
obscured by the high propensity of this organ for early
graft thrombosis that may or may not be related to rejec-
tion (2,48). Sibley (49) first described a case of hyperacute
rejection, in a patient with a negative pretransplant cross
match but high-level panel-reactive antibody (PRA) when
retested after the removal of the thrombosed organ. Sim-
ilar cases were described later, with graft loss occurring
either immediately (hyperacute rejection) or within hours
posttransplantation. As in the case reported by Sibley (49),
circulating DSA were identified retrospectively, in the set-
ting of an initially negative cytotoxic cross match (2).
Pathological findings in biopsies with severe, irreversible
AMR correspond to those observed in experimental mod-
els of hyperacute rejection (50). The earliest changes occur
within minutes of revascularization and consist of edema,
congestion, spotty acinar cell injury (i.e. vacuolization, de-
granulation and necrosis) and capillary and venular neu-
trophilic margination. Progressive graft destruction occurs
within a few hours and is characterized by confluent foci of
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Figure 2: Mild acute
AMR. (A) Exocrine area
with very subtle interstitial,
interacinar inflammation
and (B) scattered IAC
outlined with the C4d
stain. (C) Preserved lob-
ular/acinar architecture
and mild mononuclear
infiltrates that are under-
estimated on the H&E
stain. (D) CD68 stain for
macrophages in the same
area of the biopsy as (C),
demonstrates the extent of
the infiltrates (arrowheads
in C and D mark a small
duct for orientation).
hemorrhagic necrosis in acini, islets and ducts, with promi-
nent neutrophilic infiltrates and widespread fibrinoid vas-
cular necrosis and thrombosis (50). Immunoglobulin (i.e.
IgG) and complement deposition including C4d staining
are found throughout the graft vasculature (2,9).
Acute AMR
Awareness of acute AMR in pancreas allografts was
heightened by the characterization of this entity in kidney
transplants (16) and recognition of the negative impact of
circulating DSA on both short- and long-term pancreas graft
survival rates (6,11,12,51–54).
In recent years, a considerable number of studies have re-
ported the clinical and pathological findings of acute AMR
in pancreas allografts, which typically presents with graft
dysfunction. In the studies of de Kort (12), Rangel et al. (15)
and Torrealba et al. (6) exocrine abnormalities (increase in
serum amylase/lipase or decrease in urine amylase lev-
els) represented the most common indication for allograft
biopsy (55–70%) followed by combined exocrine and en-
docrine abnormalities (15–20%). Isolated endocrine dys-
function (hyperglycemia) was a relatively rare indication
for allograft biopsy (6–8%). The unusual association be-
tween AMR and pancreatic panniculitis was recently re-
ported (55).
Although approximately 75% of cases of acute AMR were
diagnosed in the first 6 months posttransplantation, late
occurring cases were not unusual (average 248 days, me-
dian 79 days, range 1–3331 days; Refs. 6,11–14,52), clearly
paralleling the clinico-pathological spectrum described with
AMR in renal allografts (17). ACMR and acute AMR could
not be distinguished from each other on clinical grounds,
stressing the importance of DSA monitoring and biopsy
evaluation (15)
The morphological findings in acute AMR may consist of
various degrees of inflammation and tissue injury as de-
tailed below:
• Acinar/interacinar inflammation
In its earlier, milder forms acute AMR presents with over-
all preservation of the architecture and mild interacinar
monocytic and/or neutrophilic infiltrates associated with
subtle spotty acinar cell dropout/apoptosis (Figures 2A
and B). In cases with predominantly monocytic inflam-
mation (i.e. few or no neutrophils), the interacinar inflam-
mation may be inconspicuous on routine H&E stains,
whereas the monocyte/macrophage infiltrates can be
highlighted with the performance of a CD68 immunos-
tain (Figures 2C and D; Refs. 6,14).
• Interacinar capillaritis
In more severe or advanced forms of acute AMR there
is dilatation and congestion of the IAC which allows for
easier identification of marginating and intraluminal in-
flammatory infiltrates (interacinar capillaritis). The latter
is similar morphologically and presumably pathogenet-
ically to peritubular capillaritis in renal allografts (56),
but in comparison to the renal peritubular capillaries,
the pancreatic IAC have a less predictable distribution
1796 American Journal of Transplantation 2011; 11: 1792–1802
Antibody-Mediated Rejection in the Pancreas





The acinar cell injury
(swelling, vacuolization
and cell dropout) appears
disproportionate to the
extent of the inflammation.
Arrowhead (A) marks
neutrophilic capillaritis.
(B and D) Severe acute
AMR represented at low
magnification to show
marked vascular conges-
tion and confluent areas
of hemorrhagic necrosis




and are relatively sparse. Furthermore in fully developed
acute AMR in pancreas allografts, extensive microvas-
cular injury leads to prominent interstitial hemorrhage,
edema and multicellular necrosis of interstitial and acinar
cells making the identification of interacinar capillaritis
more difficult (see later; Figure 3; Ref. 57). Identification
of interacinar infiltrates with associated interacinar cap-
illaritis has been found to be strongly associated with
C4d positivity and detection of DSA (6,7,12,14). In one
study capillaritis was found in >80% of biopsies with
focal and diffuse C4d positivity (6).
• Acinar cell and overall tissue injury
In pancreatic acute AMR, there is increased acinar cell
injury manifested with cytoplasmic swelling and vac-
uolization as well as apoptotic or necrotic cell dropout.
The identification of acinar cell injury in an otherwise
bland appearing biopsy (Figures 2 and 3) should alert
the pathologist to the possibility of subtle interacinar in-
flammation or capillaritis, and warrants correlation with
the C4d staining and DSA studies (6,9,12,14).
In addition to the features described earlier, very severe or
advanced forms of acute AMR have morphological fea-
tures approaching those found in hyperacute rejection.
These findings consist of widespread vascular necrosis
and thrombosis in small or larger vessels and small or con-
fluent foci of parenchymal necrosis (Figures 1D, 3B and D;
Ref. 2).
Acute AMR is graded histologically (mild, moderate or
severe) based on the extent of the interacinar infil-
trates/capillaritis and tissue damage, as presented in
Table 2.
Chronic active AMR
Chronic exposure to circulating DSA is associated with de-
velopment of graft fibrosis and graft failure (58). The his-
tological diagnosis of chronic active AMR is based on the
following triad: (i) features of acute AMR as described in
the previous section (also see Table 4; AMR diagnostic
components), (ii) absence of features of ACMR and (iii)
underlying graft fibrosis (Banff diagnostic category 6). The
utilization of this diagnostic category presupposes that the
main cause of graft fibrosis is ongoing AMR, and there-
fore requires that other causes of graft fibrosis/sclerosis
are ruled out, such as previous episodes of ACMR. In clini-
cal practice this conclusion would be most accurate when
serial biopsies are available for evaluation.
Mixed ACMR and AMR
A generalized increase in interstitial inflammation, both in
septa and acini, as well as edema were found to be more
common in biopsies with C4d positivity and concurrent
circulating DSA (12), which raises the possibility of cases
having mixed ACMR and AMR.
Stereotypical cases of isolated AMR or ACMR can be clas-
sified by a systematic evaluation of the various features
described in Table 3, but it is not unusual for the two pro-
cesses to coexist in the same biopsy (mixed rejection)
and appear with overlapping features. The pathology re-
port should clearly indicate the type of rejection present
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Table 2: Histological grading of acute antibody-mediated rejection (See Table 4∗∧ for other diagnostic components)
Grade I/Mild acute AMR
Well-preserved architecture, mild monocytic-macrophagic or mixed (monocytic-macrophagic/ neutrophilic) infiltrates with rare
acinar cell damage
Grade II/Moderate acute AMR
Overall preservation of the architecture with interacinar monocytic-macrophagic or mixed
(monocytic-macrophagic/neutrophilic) infiltrates, capillary dilatation, capillaritis, congestion, multicellular acinar cell dropout
and extravasation of red blood cells
Grade III/Severe acute AMR
Architectural disarray, scattered inflammatory infiltrates in a background of interstitial hemorrhage, multifocal and confluent
parenchymal necrosis, arterial and venous wall necrosis and thrombosis
(AMR, ACMR or mixed), estimate the degree of activity
(mild, moderate or severe) of each process and indicate
the extent of chronicity/graft fibrosis (stage).
Specific Considerations on the Updated
Banff Schema for Grading Pancreas
Allograft Rejection
1. It is now recognized that one of the main features
of acute AMR in the pancreas is the presence of
prominent acinar cell injury ranging from spotty cell
necrosis/apoptosis to confluent necrosis. Accordingly
it is now stated in the schema that Grade II and
III/Moderate and Severe ACMR, which can also present
with prominent acinar cell injury/necrosis, require dif-
ferentiation from acute AMR (Table 4).
2. Diagnosis of acute AMR is based on a combination of
diagnostic components as listed in Table 4. Criteria for
Table 3: Predominance of histological features in stereotypical
ACMR and AMR
ACMR AMR
Septal infiltrates +++ − to +
Eosinophils + to +++ − to +
Neutrophils − to ++ +/− to +++




Acinar cell injury +/– to ++ +++






+ to +++ − to+/−
Interacinar capillaritis − to +/– + to +++
Intimal arteritis + +
Necrotizing
vasculitis/thrombosis
− to + +++
Confluent hemorrhagic
necrosis




the histological grading of acute AMR (mild, moderate
or severe) are provided in a separate table (Table 2).
3. Chronic active AMR is based on the combination of
acute AMR and graft sclerosis-fibrosis (Categories 4
and 6), in the absence of ACMR (Category 3). A conclu-
sive diagnosis of chronic active AMR requires C4d pos-
itivity, interacinar inflammation/capillaritis/acinar dam-
age and circulating DSA in addition to graft sclerosis-
fibrosis. If only two of the AMR diagnostic elements
are present, a diagnosis of suspicious for chronic active
AMR can be rendered.
4. Chronic allograft arteriopathy was initially considered
to be an expression of T-cell-mediated allograft rejec-
tion (45), but recent studies have shown that acute
and chronic arterial lesions can be also associated with
DSA and AMR (59–61). Accordingly, this lesion is now
listed as a separate morphological category (indepen-
dent from ACMR and AMR). Recognition of chronic al-
lograft arteriopathy in biopsy samples is clinically impor-
tant because it indicates ongoing (chronic) alloimmune
injury and for its association with late graft thrombosis
(2).
5. A separate category has been created for lesions
specifically involving the endocrine islets. The main
purpose of this category is the recognition of recur-
rent autoimmune diabetes mellitus, characterized by
insulitis and/or selective ß cell loss (62,63). In addi-
tion, islet deposition of Amylin (also known as islet
amyloid polypeptide (IAPP)) appearing as amorphous
Congo red positive material is placed in this category.
Amylin, a protein normally cosecreted with insulin by ß
cells, accumulates in the pancreatic islets under abnor-
mal circumstances in particular hyperglycemic states
(i.e. Type 2 diabetes mellitus), pancreatitis and possible
allograft rejection (64,65). Deposition of amylin in other-
wise normal islets of pancreas allografts is usually as-
sociated with loss of glycemic control (hyperglycemia).
Acute calcineurin inhibitor toxicity (9) is also included
in this category.
The impact of AMR in pancreatic islets remains unclear.
Whereas hyperglycemia was documented in early re-
ports of AMR (13,58), this was a rare indication for
biopsy in subsequent larger studies (6,12,15). C4d
staining in islet capillary endothelium was found in
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Table 4: Banff pancreas allograft rejection grading schema—update diagnostic categories#
1. Normal. Absent inflammation or inactive septal, mononuclear inflammation not involving ducts, veins, arteries or acini.
There is no graft sclerosis. The fibrous component is limited to normal septa and its amount is proportional to the size of
the enclosed structures (ducts and vessels). The acinar parenchyma shows no signs of atrophy or injury.
2 Indeterminate. Septal inflammation that appears active but the overall features do not fulfill the criteria for mild
cell-mediated acute rejection
3. Acute T-cell-mediated rejection+
- Grade I/Mild acute T-cell-mediated rejection
Active septal inflammation (activated, blastic lymphocytes and ±eosinophils) involving septal structures: Venulitis
(subendothelial accumulation of inflammatory cells and endothelial damage in septal veins, ductitis (epithelial
inflammation and damage of ducts)
and/or
Focal acinar inflammation. No more than two inflammatory foci∧per lobule with absent or minimal acinar cell injury
- Grade II / Moderate acute T-cell-mediated rejection (requires differentiation from AMR)
Multifocal (but not confluent or diffuse) acinar inflammation (≥3 foci∧per lobule) with spotty (individual) acinar cell injury and
dropout
and/or
Mild intimal arteritis (with minimal, <25% luminal compromise)
- Grade III / Severe acute T-cell-mediated rejection (requires differentiation from AMR)
Diffuse (widespread, extensive) acinar inflammation with focal or diffuse multicellular/confluent acinar cell necrosis
and/or
Moderate or severe intimal arteritis, >25% luminal compromise.
and/or
Transmural inflammation—Necrotizing arteritis.
4. Antibody-mediated rejection (AMR, See diagnostic components below∗)
∗Confirmed circulating donor-specific antibody (DSA)
∗Morphological evidence of tissue injury (interacinar inflammation/capillaritis, acinar cell damage
swelling/necrosis/apoptosis/dropout, vasculitis, thrombosis)
∗C4d positivity in interacinar capillaries (IAC, ≥5% of acinar lobular surface)
Acute AMR 3 of 3 diagnostic components∗∧
Consistent with acute AMR 2 of 3 diagnostic components∗∧
Requires exclusion of AMR 1 of 3 diagnostic components∗
See separate table for histological grading of acute AMR∧
Chronic active antibody-mediated rejection: Combined features of categories 4∗ and 6 in the absence of features of
category 3
5. Chronic allograft arteriopathy. Arterial intimal fibrosis with mononuclear cell infiltration in fibrosis.
6. Chronic allograft rejection/graft fibrosis
- Stage I (mild graft fibrosis)
Expansion of fibrous septa; the fibrosis occupies less than 30% of the core surface but the acinar lobules have eroded,
irregular contours. The central lobular areas are normal.
- Stage II (moderate graft fibrosis)
The fibrosis occupies 30–60% of the core surface. The exocrine atrophy affects the majority of the lobules in their periphery
(irregular contours) and in their central areas (thin fibrous strands criss-cross between individual acini).
- Stage III (severe graft fibrosis)
The fibrotic areas predominate and occupy more than 60% of the core surface with only isolated areas of residual acinar
tissue and/or islets present.
7. Islet pathology
Recurrence of autoimmune DM (insulitis and/or selective ß cell loss)
Islet amyloid (amylin) deposition
8. Other histologic diagnosis. Pathologic changes not considered to be due acute and/or chronic rejection. For example,
CMV pancreatitis, PTLD, etc.
#Categories 2 to 8 may be diagnosed concurrently and should be listed in the diagnosis in the order of their clinicopathological significance.
+Histological features of stereotypical ACMR and AMR, see Table 3.
∧Histological grading of acute AMR, see Table 2.
See Ref. 9 for morphological definition of lesions of cell-mediated rejection and for list of other histological diagnosis.
approximately 20% of samples from patients with DSA
but this finding did not correlate with hyperglycemia (6).
In severe necrotizing AMR (as well as severe ACMR)
hyperglycemia typically develops, correlating with the
extent of parenchymal necrosis (2,9).
6. The proposed schema for diagnosis of AMR in pan-
creas allografts follows the same approach as the
Banff 09 update for diagnosis of acute AMR in kid-
ney allografts (66). Both schemas rely on the combina-
tion of C4d positivity, presence of circulating DSA and
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evidence of associated tissue injury for a diagnosis of
acute AMR. In both schemas, a diagnosis of suspicious
for AMR is rendered in the absence of any one of these
diagnostic components (66).
Discussion
AMR is a complex, dynamic process with protean clini-
copathological manifestations that range from cataclysmic
graft loss to various forms of allograft inflammation asso-
ciated with protracted graft sclerosis-fibrosis (67). From a
practical point of view, severe untreatable acute AMR can
be easily diagnosed on the basis of morphological criteria
alone, but a systematic approach and high degree of sus-
picion are necessary in order to recognize the milder or
more indolent and potentially treatable forms of the dis-
ease (9,17,45). Biopsy evaluation remains the gold stan-
dard for the diagnosis of allograft rejection, as clinical pa-
rameters lack specificity and cannot discriminate between
ACMR and AMR which require different therapeutic ap-
proaches (15).
Detailed histological examination, immunostaining for C4d
and serological search for circulating DSA currently repre-
sent the cornerstones for the diagnosis of AMR, although
significant questions remain with respect to determining
the most adequate tools and thresholds for this diagnosis
(16,44,67). In particular, fluctuating levels of DSA (and C4d
staining) as well as technical limitations for the identifica-
tion of DSA have been problematic (36–38). However, other
promising tools are not yet available for routine diagnosis
(3,16,68).
The schema proposed here relies on the combination of
the currently available tools (DSA, C4d and histological find-
ings), based on their perceived strengths and limitations,
and also their complementary value (12,45; see Table 4). A
diagnosis of “suspicious for AMR” increases the sensitiv-
ity of the schema by addressing the not too unlikely clini-
cal situation in which a complete constellation of elements
is not identified (i.e. only two of the three elements are
present). On the other hand, the presence of C4d positiv-
ity, DSA or tissue injury in isolation from the other elements
is not considered sufficient to warrant clinical intervention
for AMR but should prompt thorough clinicopathological
correlation and close follow-up.
Currently there is no adequate treatment for either acute
or chronic AMR. This process is currently one of the
most challenging problems in solid organ transplantation
(10,16,21). Interventions in pancreas AMR have followed
the approach used in other organs, mainly consisting of
rabbit antithymocyte globulin, intravenous immune glob-
ulin (IVIG) and plasmapheresis with or without rituximab.
Less well-established treatments include the addition of
bortezomib and/or eculizumab, but these therapies need
to be evaluated in formal clinical trials (69).
The goal of this Banff working proposal is to provide uni-
form diagnostic criteria that can be applied both for diag-
nostic and investigational purposes in pancreas transplan-
tation. Morphological classifications such as this one have
inherent limitations related to intra- and interobserver re-
producibility (70). Studies are being currently undertaken
to evaluate reproducibility issues in this specific context.
Future Direction
In the field of pancreas transplantation there are multiple
areas of investigation that require attention, some of which
are listed below.
Clinical studies
• Need for better understanding of the pathogenetic
mechanisms in AMR including better characterization
of the role of presensitization, role of surveillance
DSA/PRA, determination of meaningful clinical cut-offs
for DSA levels (e.g. highest levels vs. broader sensitiza-
tion), potential role of circulating non-HLA antidonor anti-
bodies and autoantibodies (including antiislet antibodies
and other autoantibodies to SMA or collagen), impact of
AMR on the exocrine versus endocrine components and
relationship between alloimmunity and autoimmune re-
currence.
• Single-center and multicenter studies to determine the
utility of protocol biopsies enabling identification and de-
termination of the significance of subclinical rejections,
early identification of AMR versus ACMR and refine-
ment of clinicopathological correlations.
Pathological studies
• Histopathological characterization of the inflammatory
infiltrates in AMR and ACMR (e.g. immunohistochemical
application of lymphoid markers) to improve diagnostic
yield and increase data accumulation of pathophysio-
logic significance.
• Further refinement of the morphological characterization
of microvascular and endothelial injury and study of the
pathogenesis of chronic rejection/graft sclerosis.
Molecular studies
• Application to pancreas transplantation of the currently
available tools in gene profiling, gene transcription and
proteomics to improve understanding of the patho-
genetic mechanisms of allograft rejection (ACMR, AMR
and mixed rejection) and other processes leading to graft
failure.
• Exploration of the potential use of limited microarray
analysis or multiplex polymerase chain reaction (PCR)
for obtaining diagnostic and pathophysiologic data (e.g.
PCR for Th1, Th2, Th17 cytokines or cells).
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Individual efforts in these areas will advance understand-
ing of basic mechanisms and enhance clinical manage-
ment of pancreas allografts. This review and update of
the Banff grading schema for AMR will hopefully provide
standardization, improve diagnosis and understanding and
help elucidate mechanisms of graft failure as well as target
interventions for improving long-term outcomes.
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